A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT06478043
Phase
PHASE2
Status
Completed

Conditions

  • Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.

Key Dates

First listed
Jun 27, 2024
Start date
Oct 16, 2024
Status verified
Aug 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
60 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ivonescimab and irinotecan liposome
    Subjects receive ivonescimab plus irinotecan liposome until progression.

Primary Outcome Measure

6-month PFS (progression free survival) rate [ Time Frame: From the day treatment started to 6 months ]

Related Studies